Glucose-dependent insulinotropic polypeptide is associated with lower low-density lipoprotein but unhealthy fat distribution, independent of insulin: The addition-pro study

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 2, 2016, Pages 485-493

  Møller, Cathrine Laustrup ^a   Vistisen, Dorte ^a   Færch, Kristine ^a   Johansen, Nanna Borup ^b   Witte, Daniel R ^b,c   Jonsson, Anna ^d   Pedersen, Oluf ^d   Hansen, Torben ^d   Lauritzen, Torsten ^c   Jørgensen, Marit E ^a   Torekov, Signe S ^d   Holst, Jens Juul ^d  

^a STENO DIABETES CENTER   (Denmark)

^b Danish Diabetes Academy   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; INSULIN; LOW DENSITY LIPOPROTEIN;

ABDOMINAL FAT; AGED; ARTICLE; BODY FAT DISTRIBUTION; CROSS-SECTIONAL STUDY; DIET RESTRICTION; FEMALE; HIGH RISK PATIENT; HUMAN; INTRAABDOMINAL FAT; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOLYSIS; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SEX DIFFERENCE; WAIST HIP RATIO; BLOOD; DENMARK; ECHOGRAPHY; EPIDEMIOLOGY; GENETICS; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; RISK; SEXUAL DEVELOPMENT;

ABDOMINAL FAT; ADIPOSITY; AGED; CROSS-SECTIONAL STUDIES; DENMARK; DIABETES MELLITUS, TYPE 2; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; LIPID METABOLISM; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; RISK; SEX CHARACTERISTICS;

EID: 84959351192     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3133     Document Type: Article

References (40)

1. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest. 2007;117(1):24-32.
2. Alssema M, Rijkelijkhuizen JM, Holst JJ, et al. Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT. Eur J Endocrinol. 2013;169(4):421-430.
3. Jones IR, Owens DR, Luzio S, Williams S, Hayes TM. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1989;32(9):668-677.
4. Chia CW, Odetunde JO, Kim W, Carlson OD, Ferrucci L, Egan JM. GIP contributes to islet trihormonal abnormalities in type 2 diabetes. J Clin Endocrinol Metab. 2014;99(7):2477-2485.
5. Theodorakis MJ, Carlson O, Michopoulos S, et al. Humanduodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab. 2006;290(3):E550-E559.
6. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86(8):3717-3723.
7. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagonlike peptide 1 in type 2 diabetic patients. Diabetes. 2001;50(3):609-613.
8. McIntosh CH, Widenmaier S, Kim SJ. Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). Vitam Horm. 2009;80:409-471.
9. Ebert R, Nauck M, Creutzfeldt W. Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride responses in rats. Horm Metab Res. 1991;23(11):517-521.
10. Wasada T, McCorkle K, Harris V, Kawai K, Howard B, Unger RH. Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. J Clin Invest. 1981;68(4):1106-1107.
11. Kim SJ, Nian C, McIntosh CH. Resistin is a key mediator of glucosedependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes. J Biol Chem. 2007;282(47): 34139-34147.
12. Miyawaki K,YamadaY,BanN, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 2002;8(7):738-742.
13. Asmar M, Simonsen L, Madsbad S, Stallknecht B, Holst JJ, Bülow J. Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans. Diabetes. 2010;59(9):2160-2163.
14. Asmar M, Simonsen L, Arngrim N, Holst JJ, Dela F, Bulow J. Glucose-dependent insulinotropic polypeptide has impaired effect on abdominal, subcutaneous adipose tissue metabolism in obese subjects. Int J Obes (Lond). 2014;38(2):259-265.
15. Ceperuelo-Mallafré V, Duran X, Pachón G, et al. Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance. J Clin Endocrinol Metab. 2014;99(5):E908-E919.
16. Yip RG, Boylan MO, Kieffer TJ, Wolfe MM. Functional GIP receptors are present on adipocytes. Endocrinology. 1998;139(9): 4004-4007.
17. Ahlqvist E, Osmark P, Kuulasmaa T, et al. Link between GIP and osteopontin in adipose tissue and insulin resistance. Diabetes. 2013; 62(6):2088-2094.
18. Timper K, Grisouard J, Sauter NS, et al. Glucose-dependent insulinotropic polypeptide induces cytokine expression, lipolysis, and insulin resistance in human adipocytes. Am J Physiol Endocrinol Metab. 2013;304(1):E1-E13.
19. Kim SJ, Nian C, McIntosh CH. Adipocyte expression of the glucosedependent insulinotropic polypeptide receptor involves gene regulation by PPAR and histone acetylation. J Lipid Res. 2011;52(4): 759-770.
20. Johansen NB, Hansen AL, Jensen TM, et al. Protocol for ADDITION-PRO: A longitudinal cohort study of the cardiovascular experience of individuals at high risk for diabetes recruited from Danish primary care. BMC Public Health. 2012;12:1078.
21. Lindgren O, Carr RD, Deacon CF, et al. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab. 2011;96(8):2519-2524.
22. Færch K, Torekov SS, Vistisen D, et al. Glucagon-like peptide-1 (GLP-1) response to oral glucose is reduced in pre-diabetes, screendetected type 2 diabetes and obesity, and influenced by sex: The ADDITION-PRO study. Diabetes. 2015;64(7):2513-2525.
23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
24. Schlecht I, Wiggermann P, Behrens G, et al. Reproducibility and validity of ultrasound for the measurement of visceral and subcutaneous adipose tissues. Metabolism. 2014;63(12):1512-1519.
25. Stolk RP, Wink O, ZelissenPM,Meijer R, van Gils AP, Grobbee DE. Validity and reproducibility of ultrasonography for the measurement of intra-abdominal adipose tissue. Int J Obes Relat Metab Disord. 2001;25(9):1346-1351.
26. Philipsen A, Hansen AL, Jørgensen ME, et al. Associations of Objectively Measured Physical Activity and Abdominal Fat Distribution. Med Sci Sports Exerc. 2015;47(5):983-989.
27. Philipsen A, Jørgensen ME, Vistisen D, et al. Associations between ultrasound measures of abdominal fat distribution and indices of glucose metabolism in a population at high risk of type 2 diabetes: The ADDITION-PRO study. PLoS One. 2015;10(4):e0123062.
28. Rask E, Olsson T, Söderberg S, et al. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Metabolism. 2004;53(5):624-631.
29. Seidell JC, Cigolini M, Charzewska J, et al. Fat distribution and gender differences in serum lipids in men and women from four European communities. Atherosclerosis. 1991;87(2-3):203-210.
30. Freedman DS, Jacobsen SJ, Barboriak JJ, et al. Body fat distribution and male/female differences in lipids and lipoproteins. Circulation. 1990;81(5):1498-1506.
31. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57(1):289-300.
32. Lafontan M, Langin D. Lipolysis and lipid mobilization in human adipose tissue. Prog Lipid Res. 2009;48(5):275-297.
33. Langenberg C, Sharp SJ, Schulze MB, et al. Long-term risk of incident type 2 diabetes and measures of overall and regional obesity: the EPIC-InterAct case-cohort study. PLoS Med. 2012;9(6):e1001230.
34. Hannukainen JC, Kalliokoski KK, Borra RJ, et al. Higher free fatty acid uptake in visceral than in abdominal subcutaneous fat tissue in men. Obesity (Silver Spring). 2010;18(2):261-265.
35. Ali AH, Koutsari C, MundiM,et al. Free fatty acid storage in human visceral and subcutaneous adipose tissue: role of adipocyte proteins. Diabetes. 2011;60(9):2300-2307.
36. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD. Splanchnic lipolysis in human obesity. J Clin Invest. 2004;113(11):1582-1588.
37. Boivin A, Brochu G, Marceau S, Marceau P, Hould FS, Tchernof A. Regional differences in adipose tissue metabolism in obese men. Metabolism. 2007;56(4):533-540.
38. Engelstoft MS, Egerod KL, Holst B, Schwartz TW. A gut feeling for obesity: 7TM sensors on enteroendocrine cells. Cell Metab. 2008; 8(6):447-449.
39. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993; 91(1):301-307.
40. Chia CW, Carlson OD, Kim W, et al. Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes. 2009;58(6):1342-1349.